Table 2 Pregnancy outcomes of artemether and lumefantrine use during pregnancy

Wang 1989[20]

A

0

2

0/2

0/2^a

Sowunmi et al., 1998[15]

A + MQ (22), A (23)

0

45

McGready et al. , 2001[17]

A + MQ/AS/C (10), AL (1)

–

–

1/9

Adam et al., 2004[16]

A

1

27

1/28^b

0/28

McGready et al., 2006[21]

AL

0

13*

1^c

0

McGready et al. , 2008[22]

AL

0

125

3/117 (2.6%)

0/125

1/125 (0.8%)

3/117 (2.6%)

14/99 (14.1%)

AS

0

128

10/120 (8.3%)

1/128 (0.8%)

1/128 (0.8%)

4/120 (3.3%)

20/101 (19.8%)

Kaye et al. , 2008[23]

AL

0

58

Adam et al., 2009[24]

A (48), AL (3)

51

0

2^d

0

Piola et al. , 2010[25]

AL

0

152

12/143 (8.4%)

3/144 (2.1%)

2/144 (1.4%)

3/143 (2.1%)

12/120 (10.2%)

3/144 (2.1%)

Q

0

152

17/137 (12.4%)

4/137 (2.9%)

3/137 (2.2%)

2/137 (1.5%)

16/119 (13.4%)

6/137 (4.4%)

Manyando et al. , 2010[26]

AL^e

156

348

71/504 (14.1%)

7/504 (1.4%)

9/504 (1.8%)

8/449 (1.8%) (29/449 [6.5%])^f

9.0%

11/475 (2.3%)

AL 1^st trimester

156

20/150 (13.3%)

7/159 (4.4%)^g

2/135 (1.5%)

1/130 (0.8%) (9/130 [6.9%])^f

4/135 (3%)

SP/Q^e

138

378

90/516 (17.4%)

8/516 (1.6%)

13/516 (2.5%)

SP 6/444 (1.4%) (18/444 [4.1%])^f

7.7%

11/480 (2.3%)

SP/Q 1^st trimester

138

28/135 (20.7%)

0/135

3/129 (2.3%)

3/121 (2.5%) (8/121 [6.6%])^f

2/129 (1.6%)

Sangaré et al., 2011[27]

AL (260)^h

53ⁱ

207

7/500^j